 |
|
|
| |
Up to 91% SVR rates with ritonavir-boosted danoprevir (DNVr) plus PegIFN alfa-2a (40KD)/ribavirin (P/R) in HCV genotype (G)1b-infected prior partial/null responders
|
| |
| |
Reported by Jules Levin
APASL 2013 Singapore June 6-10
G.R. Foster, J.J. Feld, I.M. Jacobson, D.M. Jensen, S. Pol, E.J. Gane, R. Rouzier, A. Wiercinska-Drapalo, P.N. Morcos, B.J. Brennan, S. Shadad, R. Kulkarni, M.T. Navarro, P. Smith, E.S. Yetzer, N.S. Shulman, on behalf of the MATTERHORN and MAD NP22660 study groups
|
| |
|
|
|
|
|
